Clinical Trials Logo
  1. Home
  2. Transitional Cell Carcinoma
  3. NCT01668459

Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel — CabB1  

Transitional Cell Carcinoma Clinical Trial

Official title:
Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.

Clinical Trial Summary

A study for patients with confirmed locally advanced or metastatic Transitional Cell Carcinoma of the bladder or upper urinary tracts who have developed progressive disease within 12 months of their platinum based chemotherapy. The study aims to compare the overall response rate of cabazitaxel treatment versus best supportive care including single agent chemotherapy.

Clinical Trial Description

Bladder cancer was the 9th most common cause of cancer worldwide in 2002. About 70% of patients have superficial tumour and 30% have invasive tumour at diagnosis. Patients with superficial tumour are treated by surgery, which is the only curative treatment. However, about 50% of these patients will relapse, and cannot be cured by local treatment in the majority of cases. The survival of untreated metastatic patients does not exceed 3 to 6 months, and systemic chemotherapy increases overall survival of patients with unresectable disease.

However, the overall survival of patients with advanced disease treated with chemotherapy remains short (14 months), which reflects a substantial unmet medical need for more effective therapy in this very poor prognosis disease.

Cabazitaxel is a new taxane, taxanes have demonstrated activity in advanced bladder cancer, and are among the most active new cytotoxic agents to be assessed in transitional cell carcinoma.

Cabazitaxel has demonstrated activity in cell lines with acquired resistance to doxorubicin, vincristine, vinblastine, paclitaxel, and docetaxel.

This is a randomised, open-label, parallel-group phase 2 study of cabazitaxel versus best supportive care (including chemotherapy).

The study is divided into three phases: screening, treatment, and follow-up. The treatment phase comprises a maximum of six three-weekly cycles of therapy, with a post treatment discontinuation visit taking place 3 weeks after last dose of treatment before the follow-up phase begins.

This phase 2 study will initially recruit 25 patients and after interim analysis will to increase to recruit 96 patients randomised between the two treatment options and the study is expected to last about 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01668459
Study type Interventional
Source University Hospital Birmingham NHS Foundation Trust
Contact
Status Completed
Phase Phase 2/Phase 3
Start date January 2013
Completion date November 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03296306 - Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Phase 3
Completed NCT00880334 - Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC Phase 2
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Withdrawn NCT04179110 - Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor Phase 2
Completed NCT00070070 - Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas Phase 1
Completed NCT00154687 - Weekly TP-HDFL in the Treatment of Advanced TCC Phase 2
Completed NCT03256877 - Detecting Transitional Cell Carcinoma From Haematuria
Withdrawn NCT04006691 - Efficacy and Safety of UGN-101 in Recurrent Patients Phase 3
Terminated NCT05052372 - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Completed NCT00714025 - A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy Phase 2
Terminated NCT01310803 - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Phase 3
Completed NCT00623831 - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Phase 1
Completed NCT00173862 - Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated NCT01438112 - Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Phase 2/Phase 3
Completed NCT00683059 - Single Agent Abraxane as Second Line Therapy in Bladder Cancer Phase 2
Recruiting NCT04811846 - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood N/A
Not yet recruiting NCT04878250 - Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder Phase 2
Completed NCT00633789 - Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Phase 2
Completed NCT00612326 - Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging N/A